Les candidats-vaccins contre le COVID-19 testés chez l’humain sont listés au bas de cette page.

 
 
Ci-dessous, une sélection de publications scientifiques (peer-reviewed) pour les vaccins actuellement utilisés en Suisse:
 
mRNA-1273 (vaccin à ARNm, Moderna et National Institute of Allergy and Infectious Diseases et Moderna)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (New England Journal of Medicine, 30.12.2020)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 (New England Journal of Medicine, 6.4.2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 (New England Journal of Medicine, 7.4.2021)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (New England Journal of Medicine, 21.4.2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines (New England Journal of Medicine, 30.6.2021)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents (New England Journal of Medicine, 11.8.2021)

 

BNT162b2 (vaccin à ARNm, BioNTech RNA Pharmaceuticals et Pfizer)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (New England Journal of Medicine, 10.12.2020)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (New England Journal of Medicine, 24.2.2021)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons (New England Journal of Medicine, 21.4.2021)

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data (Lancet, 5.5.2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants (New England Journal of Medicine, 5.5.2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (New England Journal of Medicine, 27.5.2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines (New England Journal of Medicine, 30.6.2021)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant (New England Journal of Medicine, 21.7.2021)

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting (New England Journal of Medicine, 25.8.2021)

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years (Press release, 20.9.2021)

Les vaccins de Moderna, Pfizer/BioNTech et AstraZeneca ayant déjà été homologués dans plusieurs pays, un résumé des résultats intérmédiaires des essais de phase 3 déjà disponibles pour ces vaccins est disponible ICI.

 
- Ad26.COV2.S (vaccin à vecteur, Janssen Vaccines & Prevention (Johnson & Johnson))
 
 
CVnCoV Vaccine (vaccin à ARNm, Curevac)
 
"CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria." CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV (Press release, 16.6.2021)
 
 
 
 
 
NVX-CoV2373 (protéines recombinantes, Novavax)
 
 
Autres vaccins en Phase III (efficacité et sécurité):
 
Remarque: certains de ces vaccins ont déjà été homologués dans certains pays. Pour une liste actualisée des vaccins en phases d'essais cliniques, consulter ce document de l'OMS, régulièrement mis à jour.
 

  Inactivated SARS-CoV-2 (virus inactivés, Sinovac et Butantan Institute)

Inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (virus inactivés, Hennan Provincial Center for Disease Control and Prevention et Sinopharm)

- BBIBP-CorV (virus inactivés, Beijing Institute of Biological Products Co., LTD et Laboratorio Elea Phoenix S.A.)

- Ad26.COV2.S (vaccin à vecteur, Janssen Vaccines & Prevention (Johnson & Johnson))

Ad5-nCoV (vaccin à vecteur, CanSino Biologics)

- Gam-COVID-Vac (vaccin à vecteur, Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation)

- Inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) (virus inactivés, Wuhan Provincial Center for Disease Control and Prevention)

- CoVLP (protéines recombinantes, Medicago)

BBV152 - COVAXIN (virus inactivés, Bharat Biotech International Ltd)

Recombinant new coronavirus vaccine (CHO cell) (protéines recombinantes, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.)

- AG0302-COVID19 (vaccin à ADN, AnGes Inc., Japan Agency for Medical Research and Development)

Inactivated SARS-CoV-2 Vaccine (virus inactivés, Chinese Academy of Medical Sciences)

- SCB-2019 (protéines recombinantes, Clover Biopharmaceuticals Australia)

nCov Vaccine (vaccin à ADN, Cadila Healthcare Ltd)

- QazCovid-in (virus inactivés, Research Institute for Biological Safety Problems)

- UB-612 (protéines recombinantes, United Biomedical, COVAXX)

- EpiVacCorona (protéines recombinantes, Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector")

 Liste continuellement mise à jour des candidats vaccins en phase III (en anglais)

 


Liste de tous les vaccins en phase I, II ou III, classés par type:

  • 1

Vaccine Safety Net

VSN - Vaccine Safety NetLe Vaccine Safety Net est un réseau mondial de sites Web, établi par l'Organisation mondiale de la santé, qui fournit des informations fiables sur la sécurité des vaccins.

En savoir plus...